Status:

COMPLETED

Dose Response Study of Nitisinone in Alkaptonuria

Lead Sponsor:

University of Liverpool

Collaborating Sponsors:

Liverpool University Hospitals NHS Foundation Trust

Conditions:

Alkaptonuria

Eligibility:

All Genders

18+ years

Phase:

PHASE2

Brief Summary

SONIA 1 is an international, multicentre, randomised, open-label, no-treatment controlled, parallel group, dose-response study to investigate the effect of once daily nitisinone on 24-hour urinary hom...

Eligibility Criteria

Inclusion

  • Inclusion criteria
  • A subject must fulfil the following criteria in order to be included in the study:
  • Diagnosis of alkaptonuria verified by documented elevated urinary homogentisic acid excretion.
  • Age ≥18 years.
  • Willing and able to visit the investigational site for study visits.
  • Signed written informed consent obtained.
  • Exclusion criteria
  • The presence of any of the following will exclude a subject from inclusion in the study:
  • Non-alkaptonuria causes of ochronosis.
  • Currently pregnant or lactating.
  • Known allergy to nitisinone or any of the constituents of the investigational product.
  • Use of a protein-restricted diet
  • Dietary habits or use of homeopathic therapies that interfere with tyrosine catabolism.
  • Current keratopathy, contact lens use or uncontrolled glaucoma.
  • Current malignancy.
  • Uncontrolled hypertension (blood pressure greater than 180 systolic or greater than 95 diastolic).
  • Electrocardiogram changes indicative of myocardial infarction, arrhythmia, tachycardia, bradycardia, left bundle branch block.
  • Chest radiographic abnormalities, including an infiltrative, mass, congestive heart failure, embolism, atelectasis.
  • Serum potassium \< 3.0 mmol/L.
  • eGFR \< 60 mL/min.
  • Any hepatic enzymes greater than 3 x upper limit of normal.
  • Haemoglobin \< 10.0 g/dL.
  • Platelets less than 100 x 109/L.
  • WBC less than 3.0 x 109/L.
  • ESR greater than 100 mm/h.
  • History of alcohol or drug abuse.
  • Participation in another clinical trial within 3 months of randomisation.
  • Treatment with nitisinone within 3 months of randomisation
  • Psychiatric illness or neurological disease that interferes with compliance or communication with health care personnel.
  • Any other medical condition which in the opinion of the investigator makes the subject unsuitable for inclusion.
  • Foreseeable inability to cooperate with given instructions or study procedures.

Exclusion

    Key Trial Info

    Start Date :

    May 1 2013

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    December 1 2013

    Estimated Enrollment :

    40 Patients enrolled

    Trial Details

    Trial ID

    NCT01828463

    Start Date

    May 1 2013

    End Date

    December 1 2013

    Last Update

    June 11 2014

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    Royal Liverpool Hospital

    Liverpool, Merseyside, United Kingdom, L7 8XP

    Dose Response Study of Nitisinone in Alkaptonuria | DecenTrialz